The estimated Net Worth of Jayne Gershkowitz is at least $184 Thousand dollars as of 1 July 2015. Ms Gershkowitz owns over 10,649 units of Amicus Therapeutics Inc stock worth over $184,174 and over the last 11 years she sold FOLD stock worth over $0.
Ms has made over 5 trades of the Amicus Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she exercised 10,649 units of FOLD stock worth $148,767 on 1 July 2015.
The largest trade she's ever made was exercising 10,649 units of Amicus Therapeutics Inc stock on 1 July 2015 worth over $148,767. On average, Ms trades about 3,115 units every 26 days since 2013. As of 1 July 2015 she still owns at least 16,342 units of Amicus Therapeutics Inc stock.
You can see the complete history of Ms Gershkowitz stock trades at the bottom of the page.
Jayne C. Gershkowitz is the Chief Patient Advocate at Amicus Therapeutics Inc.
Ms Gershkowitz is 64, she's been the Chief Patient Advocate of Amicus Therapeutics Inc since . There are 1 older and 17 younger executives at Amicus Therapeutics Inc. The oldest executive at Amicus Therapeutics Inc is Robert Essner, 72, who is the Independent Director.
Jayne's mailing address filed with the SEC is 1 CEDAR BROOK DRIVE, , CRANBURY, NJ, 08512.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris, and Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: